Quarterly ResultAug 13, 2026, 04:25 PM
NuCana Q2 Net Loss £3.1M; Cash Runway into 2029; Clinical Progress
AI Summary
NuCana plc reported a net loss of £3.1 million for the second quarter of 2026, a significant reduction from £24.1 million in the same period of 2025. For the first half of 2026, the net loss was £6.9 million, down from £26.6 million year-over-year. The company ended June 30, 2026, with £19.5 million in cash and cash equivalents, extending its cash runway into 2029. NuCana also announced the completion of patient recruitment for its Phase 2 NUC-7738 study, with final data expected later in 2026.
Key Highlights
- Net loss for Q2 2026 was £3.1 million, compared to £24.1 million in Q2 2025.
- Net loss for H1 2026 was £6.9 million, compared to £26.6 million in H1 2025.
- Cash and cash equivalents totaled £19.5 million as of June 30, 2026.
- Cash runway is anticipated to fund operations into 2029.
- Patient recruitment completed for Phase 2 NUC-7738 study in melanoma.
- Final data from Phase 2 NUC-7738 study expected later in 2026.
- Share-based payment expenses for H1 2026 were £2.8 million.
- Basic and diluted loss per ordinary share for H1 2026 was £0.00.
Price Impact
More from NCNA